A rapidly emerging concept that holds the promise of altering the natural history and subsequently outcomes for cancer patients is that of precision-or personalized-medicine. Precision medicine seeks to select the most effective treatment option for each individual patient's tumor, given at the appropriate time in the life cycle of the disease, and predicated upon an understanding of the specific molecular nature of the tumor with the ultimate goal of improving survival and quality of life. There is an immediate and growing need to alert advanced practitioners about the role molecular profiling has in the treatment of ovarian cancer, from a primarily prognostic role to one that can also provide predictive guidance regarding the choice of a specific therapy.
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CE INFORMATION CE Learning Objectives
After completing this educational activity, participants should be able to:
1. Recognize the differences between prognostic and predictive genomic markers in practice, and the types of cancer in which indicative markers are currently being used in practice. 2. Relate NCCN guideline recommendations regarding molecular testing in ovarian cancer, including monitoring for BRCA, and the advantages and potential limitations of findings to treatment planning. 3. Describe the goals and challenges for the future broader introduction and implementation of molecular testing into routine cancer patient care and clinical trials that may provide translational insights.
Continuing Education
Statement of Credit-Participants who successfully complete this activity (including the submission of the post-test and evaluation form) will receive a statement of credit.
Physicians. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, Harborside Medical Education, and the Journal of the Advanced Practitioner in Oncology. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses. The Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
A maximum of 1.0 contact hour may be earned for successful completion of this activity.
Provider approved by the California Board of Registered Nursing, Provider No. 13664, for 1.0 contact hour.
Pharmacists. The knowledge-based accredited educational activity is intended for pharmacists involved in the care of cancer patients. This educational activity is provided by the Annenberg Center for Health Sciences at Eisenhower.
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is assigned ACPE Universal Program #0797-9999-17-094-H01-P. This program is designated for up to 1.0 contact hour (0.1 CEU) of continuing pharmacy education credit.
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All individuals in positions to control the content of this program (eg, planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Annenberg Center for Health Sciences at Eisenhower has identified and resolved all conflicts of interest in accordance with the ACHS policies and procedures. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.
